INTRODUCTION
Vitamin E, a major lipid-soluble, chain-breaking antioxidant is an important factor protecting unsaturated fatty acid residues against (per)oxidative damage [1] . It is an essential nutrient and the major symptoms of vitamin E deficiency are neurological dysfunction, muscular weakness and reproductive failure [2, 3] . Vitamin E is a generic term for the naturally occurring tocopherols and tocotrienols and of these, α-tocopherol (α-TocH) has the highest biological activity. Dietary vitamin E is taken up by intestinal cells and resecreted in chylomicrons in proportion with the concentration of the naturally occurring tocopherols in the diet [4, 5] . Circulating chylomicrons are catabolized by lipoprotein lipase (LPL ; EC 3.1.1.34), with muscle and adipose tissue being the major sites of LPL expression [6] . LPL hydrolyses triacylglycerols (TG) from chylomicrons thereby generating nonesterified fatty acids (NEFA) for subsequent tissue uptake and metabolism. In addition to its function as lipolytic enzyme, several groups have shown that LPL can anchor TG-rich proteins and LDL to the surface of a variety of cells [7] [8] [9] , increasing surface binding and degradation of these lipoproteins [10] [11] [12] by mechanisms involving the LDL-receptor-related protein and the very-low-density lipoprotein (VLDL) receptor [13] [14] [15] . Following LPL-mediated hydrolysis of chylomicrons, core remnants are taken up by the liver and part of the lipid constituents are resecreted in newly synthesized VLDL. Studies in i o have demonstrated preferential enrichment of VLDL with RRR-α-tocopherol, a process facilitated by a hepatic α-tocopherol binding\transfer protein (α-TTP) [16] [17] [18] [19] [20] [21] .
Upon secretion into plasma, VLDL is catabolized by LPL and hepatic triacylglycerol lipase and it has been suggested that these Abbreviations used : FAME, fatty acid methyl esters ; HDL, high-density lipoproteins ; LDL, low-density lipoproteins ; LPL, lipoprotein lipase ; MCK, mouse creatine kinase ; NEFA, non-esterified fatty acids ; TG, triacylglycerols ; α-TocH, α-tocopherol ; VLDL, very-low-density lipoproteins.
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by MCK-M (13.3 nmol\g) and MCK-L (8.2 nmol\g) animals when compared with control mice (7.3 nmol\g). Excellent correlation was also observed between intracellular α-TocH and non-esterified fatty acid (NEFA) levels (r l 0.998). Although LPL activities in cardiac muscle were also increased in the transgenic mouse lines, α-TocH concentrations in the heart remained unchanged. Similarly, α-TocH levels in plasma, adipose tissue and brain were unaffected by the tissue specific overexpression of LPL in muscle. The transgenic model presented in this report provides evidence that the uptake of α-TocH in muscle is directly dependent on the level of LPL expression in i o. Increased intracellular α-TocH concentrations with increased triglyceride lipolysis and NEFA uptake might protect the myocyte from oxidative damage during increased β-oxidation.
lipolytic enzymes contribute to the distribution of α-TocH between different lipoproteins and tissues. Accordingly, the tocopherol content of adipose tissue from a patient suffering from Type I LPL deficiency was distinctly lower than that of normal subjects [22] . In such cases the mechanisms for tissue uptake of α-TocH are incapacitated. One important step during tissue uptake of α-TocH is apo-lipoprotein B\E-receptor mediated endocytosis of LDL particles [23] . However, Watanabe rabbits lacking functional LDL receptors have normal tissue concentrations of α-TocH [23] and therefore additional mechanisms for α-TocH uptake must exist. It has been suggested that LPL could facilitate α-TocH uptake by the enzyme having a bridging function between lipoproteins and cell membrane glycosaminoglycans. Indeed it has been shown in itro that LPL enhances α-TocH transfer from lipid emulsions to erythrocytes and fibroblasts [24] . Other studies have revealed that LPL facilitates the (selective) uptake of cholesteryl esters and ethers, and retinoids [25, 26] . Hence, the present study was designed to investigate the effects of LPL overexpression on the α-TocH status of various tissues with special emphasis on skeletal and cardiac muscle, the sites of specific LPL overexpression.
EXPERIMENTAL

Generation of transgenic mice
The detailed procedure of transgene generation is described elsewhere [27] . Briefly, an LPL minigene was fused with the regulatory sequences of the mouse creatine kinase (MCK) gene.
The chimaeric DNA construction was injected into the male pronucleus of fertilized eggs from superovulated females and transferred into the oviducts of surrogate females. Three transgenic mouse lines were established : a low (MCK-L), medium (MCK-M) and high (MCK-H) expression line. All animals were kept on a standard laboratory chow.
LPL activity
Epididymal fat pads, heart and thigh muscle samples were surgically removed and transferred to ice-cold tubes containing 1 ml of Dulbecco's modified Eagle's medium\2 % (w\v) BSA\2 units\ml of heparin. The samples were minced with scissors and incubated at 37 mC for 1 h. The activity of LPL in muscle and adipose tissue was assayed as described previously [28] .
Tissue sampling and homogenization
After removal, the tissue samples (80 -250 mg) were immediately frozen in liquid N # to minimize the risk of inadvertent oxidation during handling of the samples [29] . The frozen samples were homogenized in a mortar in liquid N # and transferred to preweighed Pyrex tubes with Teflon screw caps. The samples were extracted three times in a biphasic extraction system of water and CHCl $ \MeOH [2 : 1 (v\v) containing 0.2 % (v\v) acetic acid] as described previously [30] . The combined lipid extracts were dried under N # and used for NEFA or tocopherol analysis. Microscopy and histochemistry of fresh muscle specimens for fibre-type classification was performed [27] .
Fatty acid analysis
To avoid overestimation of NEFA concentrations, lipid extracts were pre-separated by TLC followed by GC analysis of fatty acid methyl esters (FAME) [31] . The band corresponding to the NEFA fraction was scraped off under Ar # and transmethylated with BF $ \MeOH in toluene [32] . NEFA recovery from TLC plates was between 96 and 105 % when heptadecanoic and linoleic acid were used as standards. Separation of FAME was performed on a HP20M column (25 m, 0.35 mm internal diameter) using a HP5890 gas chromatograph equipped with a flame ionization detector. The split ratio was approx. 5 : 1. Concentrations of the individual fatty acids were calculated by peak-area comparison with the internal standard (heptadecanoic acid).
α-TocH analysis
Excised tissues were homogenized and extracted exactly as described above. Lipid extracts were dried under Ar # , redissolved in the mobile phase used for the HPLC analysis and centrifuged at 30 000 g. before HPLC analysis. Separation of α-TocH was performed on a Nucleosil GoldPak 25 cm silica column using hexane\1 % (v\v) ethanol as the mobile phase at a flow rate of 1 ml\min [33] . Detection was by fluorescence spectroscopy with the detector set at 292 nm (excitation) and 335 nm (emission). Concentrations were calculated by peak-area comparison with external standards of known concentration.
Density-gradient ultracentrifugation of plasma
To localize α-TocH in the lipoprotein classes of control and transgenic animals, plasma pools were separated by ultracentrifugation in a two-step density gradient (Beckman TL 120 benchtop centrifuge) as described previously [34] . Tris\HCl (10 mM, pH 7.4 ; density 1.006 g\ml, 3.7 ml) was underlayered with density-adjusted plasma (1.7 ml, density 1.21 g\ml) and centrifuged at 417 000 g at r av for 2 h at 15 mC. Subsequently, 500 µl fractions were collected from the bottom of the gradient and 200 µl of ethanol and 200 µl of water were added to each fraction. The samples were mixed by vortexing and the neutral lipid fraction was extracted into 200 µl of hexane. Phase separation was achieved by centrifugation at 30 000 g and a 20 µl portion of each upper phase was analysed by HPLC. The α-TocH content was quantified as described above.
RESULTS
LPL activities and NEFA concentrations in skeletal muscle
Three independent transgenic mouse lines were created as reported previously [27] . LPL activities in skeletal muscle of controls, MCK-L, MCK-M and MCK-H animals are shown in Table 1 . LPL activities in skeletal muscle were increased 3.3-, 11.7-and 27-fold in MCK-L, MCK-M and MCK-H animals respectively when compared with control mice. As a result of LPL overexpression in skeletal muscle we observed an increase in NEFA concentrations (nmol\g of wet tissue, meanspS.D.) from 566p203 in control animals to 718p273 in MCK-L, 1432p325 in MCK-M and 2407p685 in MCK-H animals ( Table 1) . NEFA levels measured in the control animals are in agreement with values reported for different muscle types in rats [35, 36] .
Effect of muscle-specific overexpression of LPL on plasma α-TocH levels
The plasma α-TocH concentrations (meanspS.D.) were 5.8p 0.79, 4.9p1.59, 4.5p0.58 and 4.3p0.95 µM in control, MCK-L, MCK-M and MCK-H animals respectively (n l 10 for controls and n l 8 for transgenic animals), slightly lower values than reported previously for rat plasma [37, 38] . These analyses revealed a tendency towards a slight decrease in circulating α-TocH concentrations with increasing number of transgene copies but the effect was not statistically significant.
Inter-lipoprotein distribution of α-TocH
To investigate if overexpression of LPL in transgenic animals caused changes in the inter-lipoprotein distribution of α-TocH, pooled plasma samples of controls, MCK-L, MCK-M and MCK-H animals (n l 3) were subjected to density-gradient 
Figure 1 Inter-lipoprotein distribution of α-TocH in plasma
(A) Pooled human plasma, (B) pooled plasma of control mice and (C) pooled plasma of MCK-H animals. Lipoproteins were isolated by ultracentrifugation in a two-step density gradient ; the gradient (5.1 ml total volume) fractions were collected from the bottom of the tube in 500 µl portions and transferred to preweighed Eppendorf tubes for density estimation. Subsequently these samples were extracted and analysed for α-TocH concentration. 100 % corresponds to 22.5 µM (A), 6.1 µM (B) and 5.2 µM (C) respectively. #, Density ; >, α-tocopherol.
ultracentrifugation. The fractions were collected from the bottom of the tube in ten fractions which were analysed for α-TocH.
Representative results of these experiments are shown in Figure  1 . The density distribution of α-TocH in normal mouse plasma is quite different from that observed in humans where α-TocH is distributed in an almost 1 : 1 ratio between high-(HDL) and lowdensity lipoproteins (LDL) ( Figure 1A , plasma pool obtained from 6 fasting human donors, α-Toc, 22.5 µM). In normal mice, 80-95 % of total plasma α-TocH was recovered in the density region 1.10-1.15 g\ml, corresponding to mouse HDL. Musclespecific overexpression of LPL resulted in a slight shift of α-TocH from the LDL to the HDL fraction. In the LDL fraction of controls 13p6 % of α-TocH was recovered, whereas in MCK-H animals 6p1.6 % of total α-TocH was located in the LDL Table 2 summarizes the α-TocH concentrations found in skeletal muscle (fast twitch, type II fibres), cardiac muscle, adipose tissue and brain of age-matched control, MCK-L, MCK-M and MCK-H animals. Compared with controls, steady-state concentrations of α-TocH in thigh muscle were increased significantly in MCK-M (1.8-fold) and MCK-H (2.9-fold) animals ( Table 2 , P 0.01, compared with controls). The α-TocH content of muscle observed in our control animals is similar to that found for rat muscle specimens (7.3 compared with 5.1 nmol\g wet tissue [37] ). From the data shown in Table 2 it is evident that muscle-specific overexpression of LPL in mice resulted in a pronounced increase in skeletal muscle α-TocH content which was dependent on the degree of LPL overexpression. When the α-TocH levels were compared with skeletal muscle-specific LPL activity, a linear relationship between the increase in heparin-releasable LPL activity and α-TocH concentration in the corresponding muscle specimens was observed (Figure 2A , r l 0.998). In agreement with the enhanced lipolytic activity, the increase in skeletal muscle NEFA concentration was accompanied by a linear increase in α-TocH levels ( Figure 2B , r l 0.998).
α-TocH levels in skeletal muscle, cardiac muscle, adipose tissue and brain of control and transgenic animals
As reported previously, the muscle creatine kinase promoter results in a highly tissue-specific overexpression of LPL, primarily in skeletal muscle [27] . However, a moderate increase (between 1.3-and 3.7-fold) was observed also in cardiac muscle [27] . This increase in cardiac muscle-specific LPL activity did not result in increased α-TocH levels in the heart. The α-TocH concentrations (meanspS.D.) in cardiac muscle specimens obtained from controls and transgenic animals were almost identical (22.8p4.6, 20.7p3.5, 22.8p2.7 and 20.1p2.4 nmol\g wet tissue for controls, MCK-L, MCK-M and MCK-H respectively ; Table 2 ).
The α-TocH levels in adipose tissue in the three transgenic lines did not vary significantly from control levels ( Table 2) and were the highest of all tissue specimens analysed (64.4p35.3, 33.6p13.6, 47.4p30.3 and 28.0p14.8 nmol\g wet tissue for controls, MCK-L, MCK-M and MCK-H animals respectively), which supports the proposed function of adipose tissue as one of the major α-TocH storage depots [39] . Brain α-TocH concentrations were not significantly different between control and transgenic animals ( Table 2 ). Brain specimens obtained from 8-week old mice contained, on average, 9.9 nmol α-TocH\g wet tissue and the corresponding value for older animals (16 weeks) was 16.7 nmol\g wet tissue.
DISCUSSION
The results of cell culture experiments implicate LPL in the delivery of α-TocH from triglyceride-rich lipoproteins to peripheral tissues. For example, Traber and Kayden [22] have shown that the addition of bovine LPL enhanced the net transfer of fatty acids and tocopherols to erythrocytes and fibroblasts. Additional evidence that LPL is involved in α-TocH uptake in i o was obtained from patients suffering from familial chylomicronaemia caused by the inherited absence of the enzyme, these individuals had decreased or low normal levels of α-TocH in adipose tissue [22, 40] . However, to date no information is available on the role of LPL in the uptake of α-TocH in muscle, although it is a major site of LPL expression in the body.
To test the hypothesis that increased LPL expression in muscle can induce α-TocH accumulation, transgenic mouse lines expressing various amounts of human LPL in skeletal and cardiac muscle were studied. In skeletal muscle α-TocH levels rose significantly with increasing LPL activity. When α-TocH concentrations were compared with the tissue LPL activity or the intracellular NEFA concentrations, a high correlation was observed in these parameters. These results provided strong evidence in i o that LPL can enhance the uptake of α-TocH in skeletal muscle and are in accordance with earlier studies in other cell types in itro demonstrating LPL-dependent uptake of α-and γ-TocH [22] .
The fact that α-TocH is also provided to cells and tissues that do not express LPL or lack the enzyme due to a genetic defect, suggests that other mechanisms exist, in addition to LPL, for the cellular uptake of α-TocH. Since the majority of α-TocH is lipoprotein-associated, these alternative mechanisms include the receptor-mediated endocytosis of lipoproteins [22] , and the selective cellular uptake of α-TocH, which is independent of receptor-mediated, whole-particle uptake [23, 41] . However, the presence of LPL apparently represents a major determinant of the relative amount found in a given tissue. Accordingly it was shown that rat tissues expressing LPL, such as adipose tissue and muscle, contain almost 65 % of the total amount of α-TocH measured in ten different organs [37] .
The molecular mechanisms by which overexpression of LPL facilitates α-TocH uptake remain to be elucidated. Overexpression of LPL leads to enhanced chylomicron and VLDL lipolysis followed by the uptake of lipolysis products such as NEFA and α-TocH. The high correlation between LPL activity and the intracellular NEFA and α-TocH levels in skeletal muscle suggest a similar uptake mechanism for both. Several mechanisms have been proposed for cellular NEFA uptake, including transport-protein mediated processes or direct, protein-independent uptake [42] [43] [44] . Similar mechanisms might exist to facilitate α-TocH uptake and need to be addressed. Whether LPL mediates α-TocH uptake by the proposed bridging function of the enzyme or by lipoprotein particle-independent, selective uptake of α-TocH remains to be elucidated. Whereas overexpression of LPL resulted in increased α-TocH levels in skeletal muscle, cardiac α-TocH levels remained unaffected. This could be explained by the rather moderate overexpression of the LPL minigene in cardiac muscle. In fact, the highest activity was a 3.7-fold overexpression (MCK-H animals) which might not be sufficient to result in a significant increase in steady-state intracellular α-TocH levels. Because of the highly tissue-specific properties of the MCK promoter, LPL activities were not altered in any tissue other than muscle. Accordingly, α-TocH concentrations in tissues such as adipose or brain were identical with those in the corresponding tissues of control animals. In the brain, however, significantly higher α-TocH levels were observed in the older animals and could suggest an age-dependent increase as described in an earlier report [38] .
Overexpression of human LPL in skeletal and cardiac muscle of transgenic animals causes premature death from severe myopathy [27] . It is generally assumed that α-TocH deficiency can result in the development of myopathies, probably because of increased lipid peroxidation in the affected tissues [45] . Therefore our findings might reflect an extreme physiological situation of increased β-oxidation and oxidative phosphorylation in which increased cellular α-TocH concentrations serve as a defense mechanism to prevent excessive oxidative damage. As shown previously, increased NEFA uptake because of LPL overexpression in skeletal muscle causes a marked increase in the number of mitochondria and peroxisomes [27] . It is well established that these cellular organelles are implicated in the production of reactive oxygen species. In mitochondria, O # − anions are produced during oxidative phosphorylation, with complexes I and III being the major sites of free-radical pro-duction [46, 47] . In peroxisomes, β-oxidation results in the formation of H # O # [48] . In a situation of massive NEFA excess both processes potentially contribute to the formation of lipidperoxidation products and the amount of α-TocH or increased catalase activity is insufficient to suppress the initiation of lipid peroxidation. This might lead ultimately to the development of the myopathy in these animals. Since LPL represents the major determinant of the amount of NEFA that enters skeletal myocytes it makes physiological sense that, simultaneously with other factors, it controls the uptake of one of the major radical scavengers, thus maintaining the integrity of the antioxidative defence system in muscle.
